Advanced Therapies 2021 | Multiplex gene silencing for the development of allogeneic cell therapies
Sven Kili, MD, Antion Biosciences SA, Geneva, Switzerland, describes the miCAR gene construct, a novel multiplex cell engineering platform that allows gene silencing of up to six selected target genes alongside the simultaneous expression of a chimeric antigen receptor (CAR) construct, in a single transduction step. This technology is currently being utilized for the development of a range of next-generation allogeneic gene-modified cell therapies for both solid and liquid tumors, as well as other disease indications. Recent data has demonstrated the ability to silence six different constructs to the same efficacy as a single construct and the constructs are currently being evaluated in preclinical animal models. This interview took place at the Advanced Therapies Congress & Expo 2021.
Disclosures
Sven Kili has the following disclosures:
Antion Biosciences – CEO;
Sven Kili Consulting – Principal;
CCRM – Board Member;
UK Innovation Hubs – Steering Committee Chair;
LGC Corporation – SAB Member;
ISCT – BM&I Committee Chair & 2022 Annual Meeting co-chair;
BIA – CGTAC Chair;
Xintela AB – Board Member;
UCL MSc in Manufacturing & Commercialisation of Cell & Gene Therapes – Steering Committee chair
